The Role of the Ovary in the Genesis of Hyperandrogenism

The Ovary: Second Edition

Volumn , Issue , 2004, Pages 513-522

  Magoffin, Denis A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36448931195     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012444562-8/50031-8     Document Type: Chapter

References (112)

1. Franks S., White D.M. Prevalence of and etiological factors in polycystic ovarian syndrome. Ann. N.Y. Acad. Sci. 1993, 687:112-114.
2. Hoffman D.I., Klove K., Lobo R.A. The prevalence and significance of elevated dehydroepiandrosterone sulfate levels in anovulatory women. Fertil. Steril. 1984, 42:76-81.
3. Chang R.J., Laufer L.R., Meldrum D.R., DeFazio J., Lu J.K., Vale W.W., Rivier J.E., Judd H.L. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotrpoin-releasing hormone agonist. J. Clin. Endocrinol. Metab. 1983, 56:897-903.
4. Rittmaster R.S., Thompson D.L. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: The relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. J. Clin. Endocrinol. Metab. 1990, 70:1096-1102.
5. Siegel S.F., Finegold D.N., Lanes R., Lee P.A. ACTH stimulation tests and plasma dehydroepiandrosterone sulfate levels in women with hirsutism. N. Engl. J. Med. 1990, 323:849-854.
6. Selye H., Collip J.B., Thomson D.L. On the effect of the anterior pituitary-like hormone on the ovary of the hypophysectomized rat. Endocrinology 1933, 17:494-500.
7. Selye H., Collip J.B. Production of exclusively thecal luteinization and continuous oestrus with anteriorpituitary-like hormone. Proc. Soc. Exp. Biol. Med. 1933, 30:647-649.
8. Selye H., Collip J.B., Thomson D.L. Further studies on production of thecal luteinization by means of A.P.L. Proc. Soc. Exp. Biol. Med. 1933, 30:780-783.
9. Duleba A.J., Pehlivan T., Carbone R., Spaczynski R.Z. Activin stimulates proliferation of rat ovarian theca-interstitial cells. Biol. Reprod. 2001, 65:704-709.
10. Roberts A.J., Skinner M.K. Transforming growth factor-α and -β differentially regulate growth and steriodogenisis of bovine thecal cells during antral follicle development. Endocrinology 1991, 129:2041-2048.
11. Pehlivan T., Mansour A., Spaczynski R.Z., Duleba A.J. Effects of transforming frowth factors-α and -β on proliferation and apoptosis of rat theca-interstitial cells. J. Endocrinol. 2001, 170:639-645.
12. Duleba A.J., Spaczynski R.Z., Olive D.L., Behrman H.R. Effecs of insulin and insulin-like growth factors on proliferation of rat ovarian theca-interstitial cells. Biol. Reprod. 1997, 56:891-897.
13. Parrott J.A., Skinner M.K. Direct actions of kit-ligand on theca cell growth and differentiation during follicle development. Endocrinology 1997, 138:3819-3827.
14. Spaczynski R.Z., Arici A., Duleba A.J. Tumor necrosis factor-α stimulates proliferation of rat ovarian theca-interstitial cells. Biol. Reprod. 1999, 61:993-998.
15. Duleba A.J., Spaczynski R.Z., Olive D.L. Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca-interstitial cells. Fertil. Steril. 1998, 69:335-340.
16. Jakimiuk A.J., Weitsman S.R., Navab A., Magoffin D.A. Luteinizing hormone receptor, steroidogenesis acute regulatory protein and steroidogenic enzyme messenger ribonucleic acids are over-expressed in theca and granulosa cells from polycystic ovaries. J. Clin. Endocrinol. Metab. 2001, 86:1318-1323.
17. Nelson V.L., Legro R.S., Strauss J.F., McAllister J.M. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol. Endocrinol. 1999, 13:946-957.
18. Wickenheisser J.K., Quinn P.G., Nelson V.L., Legro R.S., Strauss J.F., McAllister J.M. Differential activity of the cytochrome P450 17α-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J. Clin. Endocrinol. Metab. 2000, 58:2304-2311.
19. Erickson G.F., Magoffin D.A., Dyer C.A., Hofeditz C. The ovarian androgen producing cells: a review of structure/function relationships. Endocr. Rev. 1985, 6:371-399.
20. Magoffin D.A. Regulation of differentiated functions in ovarian theca cells. Sem. Reprod. Endocrinol. 1991, 9:321-331.
21. Magoffin D.A. Evidence that luteinizing hormonestimulated differentiation of purified ovarian thecalinterstitial cells is mediated by both type I and type II adenosine 3',5'-monophosphate-dependent protein kinases. Endocrinology 1989, 125:1464-1473.
22. Magoffin D.A., Weitsman S.R. Differentiation of ovarian theca-interstitial cells in vitro: Regulation of 17α-hydroxylase messenger ribonucleic acid expression by luteinizing hormone and insulin-like growth factor-I. Endocrinology 1993, 132:1945-1951.
23. Magoffin D.A., Weitsman S.R. Insulin-like growth factor-I stimulates the expression of 3β-hydroxysteroid dehydrogenase messenger ribonucleic acid in ovarian theca-interstitial cells. Biol. Reprod. 1993, 48:1166-1173.
24. Magoffin D.A., Weitsman S.R. Effect of insulin-like growth factor-I on cholesterol side chain cleavage cytochrome P450 messenger ribonucleic acid expression in ovarian theca-interstitial cells stimulated to differentiate in vitro. Mol. Cell. Endocrinol. 1993, 96:45-51.
25. Davis J.S., Weakland L.L., West L.A., Farese R.V. Luteinizing hormone stimulates the formation of inositol triphosphate and cyclic AMP in rat granulosa cells. Biochem. J. 1986, 238:597-604.
26. Dimino M.J., Snitzer J., Brown K.M. Inositol phosphates accumulation in ovarian granulosa after stimulation by luteinizing hormone. Biol. Reprod. 1987, 37:1129-1134.
27. Allen R.B., Su H.C., Snitzer J., Dimino M.J. Rapid decreases in phosphatidylinositol in isolated luteal plasma membranes after stimulation by luteinizing hormone. Biol. Reprod. 1988, 38:79-83.
28. 2+ in isolated bovine luteal cells. J. Biol. Chem. 1987, 262:8515-8521.
29. Magoffin D.A. LH stimulation of ovarian thecalinterstitial cell differentiation: Sensitizing effect of angiotensin II. Signaling Mechanisms and Gene Expression in the Ovary 1991, 417-422. Serono Symposia, Norwell, MA. G. Gibori (Ed.).
30. Hofeditz C., Magoffin D.A., Erickson G.F. Evidence for protein kinase C regulation of ovarian thecainterstitial cell androgen biosynthesis. Biol. Reprod. 1988, 39:873-881.
31. Magoffin D.A. The ovarian androgen-producing cells: A 2001 perspective. Rev. Endocr. Metab. Dis. 2001, 3:47-53.
32. Zachow R.J., Weitsman S.R., Magoffin D.A. Ovarian androgen biosynthesis: Autocrine/paracrine regulation. Androgen Excess Disorders in Women 1996, 333-345. Lippincott-Raven, Philadelphia. R. Azziz, D. Dewailly, J.E. Nestler (Eds.).
33. Chegini N., Flanders K.C. Presence of transforming growth factor-β and their selective cellular localization in human ovarian tissue of various reproductive stages. Endocrinology 1992, 130:1707-1715.
34. Roberts V.J., Barth S., El-Roeiy A., Yen S.S.C. Expression of inhibin/activin system messenger ribonucleic acids and proteins in ovarian follicles from women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 1994, 79:1434-1439.
35. Pangas S.A., Rademaker A.W., Fishman D.A., Woodruff T.K. Localization of the activin signal transduction components in normal human ovarian follicles: Implications for autocrine and paracrine signaling in the ovary. J. Clin. Endocrinol. Metab. 2002, 87:2644-2657.
36. Teixeira Filho F.L., Baracat E.C., Lee T.H., Suh C.S., Matsui M., Chang R.J., Shimasaki S., Erickson G.F. Aberrant expression of growth differentiation factor-9 in oocytes of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2002, 87:1337-1344.
37. Attia G.R., Dooley C.A., Rainey W.E., Carr B.R. Transforming growth factor beta inhibits steroidogenic acute regulatory (StAR) protein expression in human ovarian thecal cells. Mol. Cell. Endocrinol. 2000, 170:123-129.
38. Hernandez E.R., Hurwitz A., Payne D.W., Dharmarajan A.M., Purchio A.F., Adashi E.Y. Transforming growth factor-β1 inhibits ovarian androgen production: Gene expression, cellular localization, mechanism(s), and site(s) of action. Endocrinology 1990, 127:2804-2811.
39. Fournet N., Weitsman S.R., Zachow R.J., Magoffin D.A. Transforming growth factor-β inhibits ovarian 17α-hydroxylase activity by a direct non-competitive mechanism. Endocrinology 1996, 137:166-174.
40. Hillier S.G., Yong E.L., Illingworth P.J., Baird D.T., Schwall R.H., Mason A.J. Effect of recombinant activin on androgen synthesis in cultured human thecal cells. J. Clin. Endocrinol. Metab. 1991, 72:1206-1211.
41. Sawetawan C., Carr B.R., McGree E.A., Bird I.M., Hong T.L., Rainey W.E. Inhibin and activin differentially regulate androgen production and 17α-hydroxylase expression in human ovarian thecal-like tumor cells. J. Endocrinol. 1996, 148:213-221.
42. Hillier S.G., Young E.L., Illingworth P.J., Baird D.T., Schwall R.H., Mason A.J. Effect of recombinant inhibin on androgen synthesis in cultured human thecal cells. Mol. Cell. Endocrinol. 1991, 75:R1-R6.
43. Dooley C.A., Attia G.R., Rainey W.E., Carr B.R. Bone morphogenetic protein inhibits ovarian androgen production. J. Clin. Endocrinol. Metab. 2000, 85:3331-3337.
44. Yamamoto N., Christenson L.K., McAllister J.M., Strauss J.F. Growth differentiation factor-9 inhibits 3'5'-adenosine monophosphate-stimulated steroidogenesis in human granulosa and theca cells. J. Clin. Endocrinol. Metab. 2002, 87:2849-2856.
45. Lambert-Messerlain G.M., Hall J.E., Sluss P.M., Taylor A.E., Martin K.A., Groome N.P., Crowley W.F., Schneyer A.L. Relatively low levels of dimeric inhibin circulate in men and women with polycystic ovarian syndrome using a specific two-site enzyme-linked immunosorbent assay. J. Clin. Endocrinol. Metab. 1994, 79:45-50.
46. Norman R.J., Milner C.R., Groome N.P., Robertson D.M. Circulating follistation concentrations are higher and activin concentrations are lower in polycystic ovarian syndrome. Hum. Reprod. 2001, 16:668-672.
47. Laven J.S., Imani B., Eijkemans M.J., De Jong F.H., Fauser B.C. Absent biologically relevant associations between serum inhibin B concentrations and characteristics of polycystic ovary syndrome in normogonadotrophic anovulatory infertility. Hum. Reprod. 2001, 16:1359-1364.
48. Pigny P., Cortet-Rudelli C., Decanter C., Deroubaix D., Soudan B., Duhamel A., Dewailly D. Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: Effects of being overwieght and relevance to hyperandrogenism. Fertil. Steril. 2000, 73:972-977.
49. Cortet-Rudelli C., Pigny P., Decanter C., Leroy M., Maunoury-Lefebvre C., Thomas-Desrousseaux P., Dewailly D. Obesity and serum luteinizing hormone level have an independent and opposite effect on the serum inhibin B level in patients with polycystic ovary syndrome. Fertil. Steril. 2002, 77:281-287.
50. Lockwood G.M., Muttukrishna S., Groome N.P., Matthews D.R., Ledger W.L. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: A possible mechanism regulating emergence of the dominant follicle. J. Clin. Endocrinol. Metab. 1998, 83:1730-1735.
51. Eldar-Geva T., Spitz I.M., Groome N.P., Margalioth E.J., Homburg R. Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome. Hum. Reprod. 2001, 16:2552-2556.
52. Magoffin D.A., Jakimiuk A.J. Inhibin A, inhibin B and activin A concentrations in follicular fluid from women with polycystic ovary syndrome. Hum. Reprod. 1998, 13:2693-2698.
53. Erickson G.F., Chung D.-G., Sit A., DePaolo L.V., Shimasaki S., Ling N. Follistatin concentrations in follicular fluid of normal and polycystic ovaries. Hum. Reprod. 1995, 10:2120-2124.
54. Daya A., Gunby J., Hughes E.G., Collins J.A., Sagle M.A. Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: A meta-analysis. Fertil. Steril. 1995, 64:347-354.
55. Eden J.A., Jones J., Carter G.D., Alaghband-Zadeh J. Follicular fluid concentrations of insulin-like growth factor 1, epidermal growth factor, transforming growth factor-alpha and sex-steroids in volume matched normal and polycystic human follicles. Clin. Endocrinol. 1990, 32:395-405.
56. Mason H.D., Carr L., Leake R., Franks S. Production of transforming growth factor-α by normal and polycystic ovaries. J. Clin. Endocrinol. Metab. 1995, 80:2053-2056.
57. Reeka N., Berg F.D., Brucker C. Presence of transforming growth factor alpha and epidermal growth factor in human ovarian tissue and follicular fluid. Hum. Reprod. 1998, 13:2199-2205.
58. Zachow R.J., Tash J.S., Terranova P.F. Tumor necrosis factor-α attenuation of luteinizing hormone-stimulated androstenedione production by ovarian thecainterstitial cells: Inhibition at loci with the adenosine 3',5'-monophosphate-dependent signaling pathway. Endocrinology 1993, 133:2269-2276.
59. Chen H., Marcinkiewicz J.L., Sancho-Tello M., Hunt J.S., Terranova P.F. Tumor necrosis factor-α gene expression in mouse oocytes and follicular cells. Biol. Reprod. 1993, 48:707-714.
60. Gonzalea F., Thusu K., Abdel-Rahman E., Prabhala A., Tomani T., Dandona P. Elevated serum levels of tumor necrosis factor-alpha in normal-weight women with polycystic ovary syndrome. Metabolism 1999, 48:437-441.
61. Jasper M., Norman R.J. Immunoreactive interleukin-I beta and tumour necrosis factor-alpha in thecal, stromal and granulosa cell cultures from normal and polycystic ovaries. Hum. Reprod. 1995, 10:1352-1354.
62. Burghen G.A., Givens J.R., Kitabchi A.E. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 1980, 50:113-116.
63. Legro R.S., Finegood D., Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1998, 83:2694-2698.
64. Ehrmann D.A., Sturis J., Byrne M.M., Karrison T., Rosenfield R.L., Polonsky K.S. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J. Clin. Invest. 1995, 96:520-527.
65. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr. Rev. 1997, 18:774-800.
66. Barbieri R.L., Smith S., Ryan K.J. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil. Steril. 1988, 50:197-212.
67. Bergh C., Carlsson B., Olsson J.-H., Selleskog U., Hillensjo T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil. Steril. 1993, 59:323-331.
68. El-Roeiy A., Chen X., Roberts V.J., Shimasaki A., Ling N., LeRoith D., Roberts C.T., Yen S.S.C. Expression of the genes encoding the insulin-like growth factors (IGF-I and II), the IGF and insulin receptors, and IGF-binding proteins-1-6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries. J. Clin. Endocrinol. Metab. 1994, 78:1488-1496.
69. Franks S., Gilling-Smith C., Watson H., Willis D. Insulin action in the normal and polycystic ovary. Endocrinol. Metab. Clin. North Am. 1999, 28:361-378.
70. Gilling-Smith C., Story H., Rogers V., Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin. Endocrinol. (Oxf) 1997, 47:93-99.
71. Gilling-Smith C., Willis D.S., Beard R.W., Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J. Clin. Endocrinol. Metab. 1994, 79:1158-1165.
72. Barbieri R.L., Makris A., Randall R.W., Daniels G., Kistner R.W., Ryan K.J. Insulin stimulates androgen accumulation in incubations of ovrian stroma obtained from women with hyperandrogenism. J. Clin. Endocrinol. Metab. 1986, 62:904-910.
73. Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr. Rev. 1991, 12:3-13.
74. Nestler J.E., Jakubowicz D.J., de Vargas A.F., Brik C., Quintero N., Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositol glycan mediators as the signal transduction system. J. Clin. Endocrinol. Metab. 1998, 83:2001-2005.
75. Willis D., Franks S. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J. Clin. Endocrinol. Metab. 1995, 80:3788-3790.
76. Froesch E.R., Zapf J. Insulin-like growth factors and insulin: Comparative aspects. Diabetologia 1985, 28:485-493.
77. LeRoith D., Werner H., Neuenschwander S., Kalebic T., Helman L.J. The role of the insulin-like growth factor-I receptor in cancer. Ann. N.Y.Acad. Sci. 1995, 766:402-408.
78. Nestler J.E., Jakubowicz D.J. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N. Engl. J. Med. 1996, 335:617-623.
79. Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1996, 81:3299-3306.
80. Acbay O., Gundogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome?. Fertil. Steril. 1996, 65:946-949.
81. Sattar N., Hopkinson Z.E., Greer I.A. Insulinsensitizing agents in polycystic ovary syndrome. Lancet 1998, 351:305-307.
82. Widen E.I., Eriksson J.G., Groop L.C. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 1992, 41:354-358.
83. Galuska D., Nolte L.A., Zierath J.R., Wallberg-Henriksson H. Effect of metformin on insulinstimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia 1994, 37:826-832.
84. Nestler J.E., Jakubowicz D.J. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J. Clin. Endocrinol. Metab. 1997, 82:4075-4079.
85. Diamanti-Kandarakis E., Mitrakou A., Raptis S., Tolis G., Duleba A.J. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1998, 83:2699-2705.
86. La Marca A., Egbe T.O., Morgante G., Paglia T., Ciani A., de Leo V. Metformin treatment reduces ovarian cytochrome P-450c17 response to human chorionic gonadotrophin in women with insulin resistance-polycystic ovary syndrome. Hum. Reprod. 2000, 15:21-23.
87. Saltiel A.R., Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996, 45:1661-1669.
88. Buse J.B., Gumbiner B., Mathias N.P., Nelson D.M., Faja B.W., Whitcomb R.W. Troglitazone use in insulin-treated type 2 diabetic patients. Diabetes Care 1998, 21:1455-1461.
89. Fonseca V.A., Valiquett T.R., Huang S.M., Ghazzi M.N., Whitcomb R.W. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study. The troglitazone study group. J. Clin. Endocrinol. Metab. 1998, 83:3169-3176.
90. Park K.S., Ciaraldi T.P., Abrams-Carter L., Mudaliar S., Nikoulina S.E., Henry R.R. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese, type II diabetic subjects. J. Clin. Endocrinol. Metab. 1998, 83:1636-1643.
91. Hasegawa I., Murakawa H., Suzuki M., Yamamoto Y., Kurabayashi T., Tanaka K. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil. Steril. 1999, 71:323-327.
92. Arlt W., Auchus R.J., Miller W.L. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta-hydroxysteroid dehydrogenase. J. Biol. Chem. 2001, 276:16767-16771.
93. Geffner M.E., Kaplan S.A., Bersch N., Golde D.W., Landaw E.M., Chang R.J. Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. Fertil. Steril. 1986, 45:327-333.
94. Dunaif A., Green G., Futterweit W., Dobrjansky A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 1990, 70:699-704.
95. Lasco A., Cucinotta D., Gigante A., Denuzzo G., Pedulla M., Trifiletti A., Frisina N. No changes of peripheral insulin resistance in polycystic ovary syndrome after long-term reduction of endogenous androgens with leuprolide. Eur. J. Endocrinol. 1995, 133:718-722.
96. Diamanti-Kandarakis E., Mitrakou A., Hennes M.M., Platanissiotis D., Kaklas N., Spina J., Georgiadou E., Hoffman R.G., Kissebah A.H., Raptis S. Insulin senstivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 1995, 44:525-531.
97. Vidal-Puig A., Munoz-Torres M., Garcia-Calvente C., Jodar-Gimeno E., Lardelli P., Ruiz-Requena M.E., Escobar-Jiminez F. Reduction of endogenous, ovarian and adrenal androgens with ketoconazole does not alter insulin response in the polycystic ovary syndrome. J. Endocrinol. Invest. 1994, 17:647-652.
98. Ezzell C. The molecular link between fat and female fertility. J. NIH Res. 1996, 8:24-25.
99. Caro J.F., Sinha M.K., Kolaczynski J.W., Zhang P.L., Considine R.V. Leptin: The tale of an obesity gene. Diabetes 1996, 45:1455-1462.
100. Maffei M., Halaas J., Ravussin E., Pratley R.E., Lee G.H., Zhang Y., Fei H., Kim S., Lallone R., Ranganathan S., Kern P.A., Friedman J.M. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nature Med. 1995, 1:1155-1161.
101. Considine R.V., Sinha M.K., Heiman M.L., Krauciunas A., Stephens T.W., Nyce M.R., Ohannesian J.P., Marco C.C., McKee L.J., Bauer T.L., Caro J.F. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1996, 334:292-295.
102. Dagogo-Jack S., Fanelli C., Paramore D., Brothers J., Landt M. Plasma leptin and insulin relationships in obese and nonobese humans. Diabetes 1996, 45:695-698.
103. Fedorcsak P., Toreng R., Ale P.O., Anbo T., Orjesen P., Rbancsek J., Byholm T. Leptin and leptin binding activity in the preovulatory follicle of polycystic ovary syndrome patients. Scand. J. Clin. Lab. Invest. 2000, 60:649-655.
104. Magoffin D.A., Duggal P.S., Norman R.J. The role of leptin in polycystic ovary syndrome. Leptin and Reproduction 2003, (in press), Kluwer Academic/Plenum Publishers, New York. M.C. Henson, V.D. Castracane (Eds.).
105. Agarwal S.K., Vogel K., Weitsman S.R., Magoffin D.A. Leptin antagonizes the insulin-like growth factor-I augmentation of steroidogenesis in granulosa and theca cells of the human ovary. J. Clin. Endocrinol. Metab. 1999, 84:1072-1076.
106. Karlsson C., Lindell K., Svensson E., Bergh C., Lind P., Billig H., Carlsson L.M.S., Carlsson B. Expression of functional leptin receptors in the human ovary. J. Clin. Endocrinol. Metab. 1997, 82:4144-4148.
107. Steppan C.M., Brown E.J., Wright C.M., Bhat S., Banerjee R.R., Dai C.Y., Enders G.H., Silberg D.G., Wen X., Wu G.D., Lazar M.A. A family of tissue-specific resistin-like molecules. Proc. Natl. Acad. Sci. USA 2001, 98:502-506.
108. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., Patel H.R., Ahima R.S., Lazar M.A. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
109. Savage D.B., Sewter C.P., Klenk E.S., Segal D.G., Vidal-Puig A., Considine R.V., O'Rahilly S. Resistin/FIZZ3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001, 50:2199-2202.
110. Nagaev I., Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem. Biophys. Res. Commun. 2001, 285:561-564.
111. Janke J., Engeli S., Gorzelniak K., Luft F.C., Sharma A.M. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes. Res. 2002, 10:1-5.
112. McTernan P.G., McTernan C.L., Chetty R., Jenner K., Fisher F.M., Lauer M.N., Crockeer J., Barnett A.H., Kumar S. Increased resistin gene and protein expression in human abdominal adipose tissue. J. Clin. Endocrinol. Metab. 2002, 87:2407-2410.